sicklecellanemianews1d
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
BioSpace16h
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer Inc. (NYSE:PFE) has divested a $3.3 billion stake in Haleon (NYSE:HLN), reducing its holding in the British consumer ...
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...